Literature DB >> 17517439

Abnormal interleukin 1 receptor types I and II gene expression in eutopic and ectopic endometrial tissues of women with endometriosis.

Christine Lawson1, Nathalie Bourcier, Mahéra Al-Akoum, Rodolphe Maheux, Françoise Naud, Ali Akoum.   

Abstract

Interleukin-1 (IL1) is believed to play a central role in the immuno-inflammatory process associated with endometriosis. IL1 triggers cell activation via its receptor type I (IL1R1), but its receptor type II (IL1R2) is known instead as a scavenger that buffers the cytokine's effects. Our previous studies have shown increased expression of IL1R1 in active endometriotic implants compared to normal and endometriosis women-derived endometrial tissues, and a simultaneous decrease in IL1R2 expression at the protein level. In the present study, in situ hybridization demonstrated a noticeable decrease in IL1R2 mRNA hybridization score in eutopic and matched ectopic endometrial tissues of women with endometriosis compared to normal women in the stroma (P<0.001 and P<0.001, respectively) and the epithelium (P<0.01 and P<0.05, respectively), whereas IL1R1 mRNA hybridization score was higher only in the ectopic implants, with a statistically significant difference in the stroma (P<0.05). This was corroborated by RT-PCR analysis of IL1R1 and IL1R2 mRNAs in ectopic (P<0.05 and P<0.05, respectively) and matched eutopic (P=0.22 and P<0.05, respectively) endometrial tissues from women with endometriosis compared to endometrial tissues from normal women. The decrease in IL1R2 mRNA levels in eutopic endometrial tissue of endometriosis women, and the concomitant increase in IL1R1 mRNA levels in ectopic implants, reveal a profound defect in IL1R 1 and IL1R2 gene expression which may accentuate the capability of this tissue to respond to IL1 and favor its ectopic growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517439     DOI: 10.1016/j.jri.2007.04.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  7 in total

1.  COUP-TFII regulates human endometrial stromal genes involved in inflammation.

Authors:  Xilong Li; Michael J Large; Chad J Creighton; Rainer B Lanz; Jae-Wook Jeong; Steven L Young; Bruce A Lessey; Wilder A Palomino; Sophia Y Tsai; Francesco J Demayo
Journal:  Mol Endocrinol       Date:  2013-10-31

2.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.

Authors:  Mamadou Keita; Paul Bessette; Manuella Pelmus; Youssef Ainmelk; Aziz Aris
Journal:  J Ovarian Res       Date:  2010-01-28       Impact factor: 4.234

3.  Association of the Precursor of Interleukin-1β and Peritoneal Inflammation-Role in Pathogenesis of Endometriosis.

Authors:  Justyna Sikora; Aleksandra Mielczarek-Palacz; Zdzisława Kondera-Anasz
Journal:  J Clin Lab Anal       Date:  2016-03-28       Impact factor: 2.352

4.  Functional microRNA involved in endometriosis.

Authors:  Shannon M Hawkins; Chad J Creighton; Derek Y Han; Azam Zariff; Matthew L Anderson; Preethi H Gunaratne; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2011-03-24

Review 5.  Endometrial biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Devashana Gupta; M Louise Hull; Ian Fraser; Laura Miller; Patrick M M Bossuyt; Neil Johnson; Vicki Nisenblat
Journal:  Cochrane Database Syst Rev       Date:  2016-04-20

6.  NLRP3 Inflammasome Activation of Mast Cells by Estrogen via the Nuclear-Initiated Signaling Pathway Contributes to the Development of Endometriosis.

Authors:  Xinyue Guo; Xinxin Xu; Tiantian Li; Qin Yu; Jianzhang Wang; Yichen Chen; Shaojie Ding; Libo Zhu; Gen Zou; Xinmei Zhang
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

7.  The Aryl hydrocarbon receptor mediates reproductive toxicity of polychlorinated biphenyl congener 126 in rats.

Authors:  Violet Klenov; Susanne Flor; Shanthi Ganesan; Malavika Adur; Nazmin Eti; Khursheed Iqbal; Michael J Soares; Gabriele Ludewig; Jason W Ross; Larry W Robertson; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2021-07-10       Impact factor: 4.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.